Table 3.
Frequency of mild-to-moderate adverse events on days 1–7 (related or not to treatment) with three artemisinin-containing combinations therapies in comparison with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)
|
AS-SMP |
AS-AQ |
AL |
AQ-SP |
p | |
|---|---|---|---|---|---|
| N = 58 | N = 68 | N = 60 | N = 65 | ||
| At least one adverse event |
24 |
35 |
17 |
32 |
0.037 |
| % (95% CI) |
41% (29–55) |
51% (39–64) |
28% (17–41) |
49% (37–62) |
|
| Vomiting |
10 |
12 |
4 |
12 |
0.177 |
| Fever |
11 |
14 |
8 |
6 |
0.143 |
|
Fatigue |
4 |
9 |
3 |
16 |
0.006 |
| Abdominal pain |
3 |
8 |
2 |
9 |
0.112 |
| Diarrhoea |
4 |
6 |
4 |
5 |
0.976 |
| Anorexia |
3 |
4 |
3 |
8 |
0.377 |
| Pruritus |
2 |
4 |
0 |
4 |
0.222 |
| Drowsiness |
0 |
0 |
0 |
2 |
0.175 |
| Aphthous stomatitis |
0 |
1 |
0 |
1 |
1.000 |
| Headache |
1 |
0 |
1 |
0 |
0.359 |
| Other* | 6 | 7 | 3 | 6 | 0.666 |
AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number; CI, Confidence interval. In bold: the only adverse event for which statistically significant differences (p <0.01) are observed between the treatments.
*Intestinal, respiratory, skin infections, pain, anaemia, cough, injuries, skin rash.